Home
Our Team
- About
Technology
Pipeline
Partnerships
Newsroom
- Events
Careers
Contact

Select Page

VANCE: First in Human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine

News & Updates

HELLO WORLD

ILLUSTRATOR

WRITER

WEB-DESIGNER

VANCE: First in Human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine

Jun 5, 2018

View/Download ASCO 2018 Poster

Search for:

Recent Posts

Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine
First peer-reviewed results of Phase 3 human trials of Oxford vaccine demonstrate efficacy
Vaccitech Chief Scientific Officer Dr. Thomas Evans on COVID-19 vaccination
Vaccitech Co-Founder Professor Adrian Hill on Developing a Covid-19 Vaccine
Oxford University breakthrough on global COVID-19 vaccine

Archives

December 2020
November 2020
October 2020
September 2020
August 2020
July 2020
June 2020
April 2020
March 2020
February 2020
January 2020
December 2019
November 2019
October 2019
August 2019
July 2019
June 2019
May 2019
March 2019
December 2018
October 2018
September 2018
June 2018
March 2018
January 2018
October 2017
November 2016
August 2016
July 2016

Vaccitech Limited

The Schrödinger Building
Heatley Road
The Oxford Science Park
Oxford
OX4 4GE

T: +44 (0)1865 818808

Home
About
Sitemap
Privacy Policy
Privacy Notice
Careers
Contact

Vaccitech is a T cell immunotherapy and vaccine company developing products to treat and prevent infectious disease and cancer

Twitter
LinkedIn

© Vaccitech 2021 All rights reserved. Website by Brand Cooke